Glenmark Pharmaceuticals Limited announced that its Board of Directors, at a meeting held on May 29, 2026, recommended a final dividend of Rs 2.5 per equity share for the financial year ended March 31, 2026. The dividend represents 250% on the face value of Re 1 per share and is subject to shareholder approval at the upcoming Annual General Meeting.
The company reported consolidated revenue from operations of Rs 1,698.25 crore for FY2026, compared to Rs 1,332.17 crore in FY2025, marking a significant year-on-year growth. Standalone revenue from operations stood at Rs 844.01 crore for the fiscal year.
Consolidated profit after tax for FY2026 was Rs 136.20 crore, while standalone PAT reported a loss of Rs 20.08 crore for the same period. The consolidated basic earnings per share for FY2026 was Rs 48.26, compared to Rs 37.11 in the previous fiscal year.
For the fourth quarter ended March 31, 2026, Glenmark's consolidated net sales were Rs 376.03 crore, with total revenue from operations at Rs 377.06 crore. The standalone Q4 net sales were Rs 220.76 crore.
The company's paid-up equity share capital stood at Rs 28.22 crore as of March 31, 2026. The Board also approved the audited financial results for the quarter and year ended March 31, 2026, which have been filed with the stock exchanges.
Disclaimer: This article is based on company filings submitted to the Bombay Stock Exchange (BSE) and National Stock Exchange of India (NSE) and is for informational purposes only. It does not constitute investment advice or a recommendation. Investors should conduct their own research and consult a qualified financial advisor before making investment decisions.